Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.69 (
BMT
)
2,655
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Three patients who developed acute onset of cerebral
blindness
within 5-47 days of
BMT
using tacrolimus (FK506) as primary GVHD prophylaxis are described. This syndrome has been described with the use of cyclosporin A (CsA) and FK506 in solid organ transplant recipients. CsA-induced cerebral
blindness
has also been noted in
BMT
recipients but to date there have been no reports of this complication in
BMT
patients receiving FK506. We have noted a striking similarity in the clinical and radiographic presentations between these patients and those with CsA-associated cerebral
blindness
. Reversibility within 1-2 weeks of onset and the potential for substitution of CsA for FK506 in these patients is described.
...
PMID:Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. 887 19
We report the case of a
BMT
recipient who developed
blindness
22 months after
BMT
. Microvascular retinopathy, cortical
blindness
and other ocular pathologies were excluded with appropriate tests. Electrophysiological studies showed retinal damage without excluding an optic nerve lesion. The patient, who had several risk factors for neurologic-induced cyclosporine toxicity, improved with cyclosporine withdrawal. Our findings stress the need of electrophysiological tests to exclude neuroretinal damage in patients receiving cyclosporine after
BMT
.
...
PMID:Cyclosporine-induced retinal toxic blindness. 925 93
A 23-year-old woman underwent HLA-matched unrelated
BMT
for CML. She developed cerebral
blindness
on day 81. Brain magnetic resonance imaging revealed hyperintensity on a T2-weighted image in the white and gray matter of the right frontal and both occipital lobes. Single-photon emission computed tomography (SPECT) was consistent with a decrease in radionuclide uptake in these areas, suggesting a vasoconstrictive mechanism. A diagnosis of CsA-induced encephalopathy was made and CsA was discontinued. Her vision recovered completely after 24 h and abnormal imaging resolved within 2 weeks. This case demonstrates late onset CsA-induced cerebral
blindness
with the previously unreported abnormalities on SPECT.
...
PMID:Late onset cyclosporine-induced cerebral blindness with abnormal SPECT imagings in a patient undergoing unrelated bone marrow transplantation. 1091 13